Mode
Text Size
Log in / Sign up
N/A Completed N=282 Randomized Double-blind Treatment

A Clinical Study of the ACRYSOF® IQ EDF Intraocular Lens (IOL)

Source: ClinicalTrials.gov NCT03010254 ↗
Enrolled (actual)
282
Serious AEs
1.7%
Results posted
Apr 2020
Primary outcomePrimary: Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 Centimeters (cm) — 0.175; 0.313 logMAR — p=<0.001

Summary

The purpose of the study is to demonstrate the safety and performance of the ACRYSOF® IQ EDF IOL.

Outcome Measures

OutcomeResultp-value
PRIMARY
Monocular Photopic Distance Corrected Intermediate Visual Acuity (DCIVA) at 66 Centimeters (cm)
0.175; 0.313 <0.001 sig
PRIMARY
Percentage of Subjects With Ocular Adverse Events
0.6; 0.0; 0.0; 0.0; 0.0; 0.0 —
SECONDARY
Monocular Photopic Best Corrected Distance Visual Acuity (BCDVA) at 4 Meters (m)
-0.007; -0.044 —
SECONDARY
Monocular Photopic Distance Corrected Near Visual Acuity (DCNVA) at 40 cm
0.420; 0.510 <0.001 sig
SECONDARY
Monocular Photopic Distance Corrected Depth of Focus Assessed by the Mean Defocus Curve
1.61; 1.09 —
SECONDARY
Monocular Mesopic Contrast Sensitivity at 12 Cycles Per Degree (Cpd)
0.799; 0.978; 0.794; 0.975 —
SECONDARY
Percentage of Subjects Who Respond "Never" to Question 1 of the Spectacle Use Questionnaire: "How Often Do You Wear Eyeglasses for Any Purpose?"
30.2; 10.0 —
SECONDARY
Percentage of Subjects Who Respond "Never" to Question 3 of the Spectacle Use Questionnaire: "How Often Do You Wear Eyeglasses for Intermediate Tasks (e.g., Computer)?"
75.5; 53.8 —

Eligibility Criteria

Inclusion Criteria

  • Able to understand and sign an Independent Ethics Committee (IEC)/ Institutional Review Board (IRB) approved Informed Consent Form;
  • Diagnosed with cataract in both eyes;
  • Planned cataract removal by routine small incision surgery;
  • Calculated IOL power is within the clinical study supply range (18.0-25.0 diopter (D) in 0.5 D steps);
  • Preoperative regular astigmatism of less than 1.0 D.

Exclusion Criteria

  • Pregnancy or lactation current or planned during the course of the study;
  • History of anterior segment (corneal, anterior chamber, sulcus) or posterior segment (uveal, vitreo-retinal) pathology including retinal vascular occlusive disease, retinal detachment or peripheral retinal laser photocoagulation, age-related macular degeneration (ARMD), glaucoma (uncontrolled or controlled with medication) or ocular hypertension, diabetic retinopathy, retinitis pigmentosa and any optic nerve pathology.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03010254). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search